Phenomenology and Content of the Inhaled N, N-Dimethyltryptamine (N, N-DMT) Experience
Qualitative analysis of 3,778 inhaled N,N‑DMT reports posted to r/DMT (2009–2018) identified consistent phenomenological themes, including common somatic effects (notably somaesthesias), vivid fractal and colourful visualisations, and frequent entity encounters (45.5%) often characterised as feminine, alien, deity or mythological figures that were predominantly benevolent or guide‑like. Respondents also described recurrent "DMT world" architectures (rooms, tunnels, higher dimensions), frequent mystical and ego‑dissolution experiences, and occasional challenging responses and statements of profundity.
Authors
- Robin Carhart-Harris
- Christopher Timmermann
- Roland Griffiths
Published
Abstract
Background
Understanding the phenomenology and content of the inhaled N, N, dimethyltryptamine (N, N-DMT) experience is critical to facilitate and support ongoing research and therapeutic models targeting mental health conditions and central nervous system pathology.
Methods
Qualitative analysis of all N, N-DMT experiences posted to the r/DMT Reddit community over a 10-year period from 2009-2018.
Results
A total of 3778 experiences from 3305 posts were included in this study. A median dose of N, N-DMT of 40.0 mg [interquartile range (IQR), 27.5 to 50.0] and a median experience duration of 10 minutes (IQR, 5.0 to 15.0) were identified. The most common somatic effects were somaesthesias (n=1415, 37.5%) and an auditory ringing (n=583, 15.4%). Visualizations predominantly consisted of fractals, shapes, patterns (n=1231, 32.5%) and vivid colours (n=953, 25.2%). Entity encounters occurred in 45.5% (n=1719) of the experiences and involved predominantly a feminine phenotype (n=416, 24.2%); aliens (n=281, 16.3%); deities (n=238, 13.8%); creature-based entities (n=158, 9.2%, including reptilian and insectoid beings); mythological beings (n=138, 8.0%, including machine elves); and jesters (n=112, 6.5%). Entity interactions were predominantly positive (n=600, 34.9% of encounters) involving benevolent, comforting, protecting, or outwardly caring interactions. A companion-type, pedagogical, or guide-type interaction was identified 32.4% of encounters (n=557). Common typology, architectural, and structural features of the “DMT world” were descriptions of alternate or higher dimensions (n=952, 25.2%); room(s) [n=582, 15.4%, including the “waiting room” (n=105, 2.8%)], and a tunnel (n=390, 10.3%). Features of mystical and ego-dissolution experiences were common and additional rewarding aspects were reported, including familiarity and acceptance/removal of the fear of death. Challenging and difficult responses were less frequent but also documented. Statements of profundity were identified in 232 experiences (6.1%), including pronouncing the experience or an aspect of the experience as the most “beautiful” or feeling the most “beautiful” of their life (n=47, 1.2%).
Conclusion
This study identified common phenomenological themes and content of naturalistic inhaled N, N-DMT experiences. Major thematic domains included (1) physical and somatic experiences; (2) content of visualizations and imagery; (3) entity encounters including entity phenotype, descriptors, attributes, disposition, and characteristics of the interaction; (4) typology, architectural features, structural characteristics, and scenery of the “DMT world”; (5) emotional responses (including positive, rewarding, difficult, and challenging); and (6) statements of profundity.
Research Summary of 'Phenomenology and Content of the Inhaled N, N-Dimethyltryptamine (N, N-DMT) Experience'
Introduction
N,N-Dimethyltryptamine (DMT) is a naturally occurring classic psychedelic whose psychoactive properties are mediated primarily through serotonin 5-HT2A receptor agonism. Plant-based DMT has been central to indigenous Amazonian ceremonial practice for centuries, most notably through the oral preparation ayahuasca. Inhaled synthetic DMT produces an extremely rapid and intense psychedelic state lasting approximately 15 to 30 minutes, distinguished by vivid geometric visuals, the dissolution of ordinary boundaries of self and world, and — in a substantial proportion of users — encounters with seemingly autonomous entities. Despite these distinctive phenomenological features, systematic large-scale characterisation of the content of inhaled DMT experiences had not been conducted at the time of this study. This study aimed to document the phenomenological content of naturalistic inhaled DMT experiences through structured qualitative analysis of ten years of posts to the r/DMT community on Reddit, generating a comprehensive empirical taxonomy of experiential features across a large sample.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Authors
- APA Citation
Lawrence, D. W., Carhart-Harris, R., Griffiths, R., & Timmermann, C. (2022). Phenomenology and Content of the Inhaled N, N-Dimethyltryptamine (N, N-DMT) Experience. https://doi.org/10.21203/rs.3.rs-1559063/v1
References (27)
Papers cited by this study that are also in Blossom
McKenna, D., Towers, G. H., Abbott, F. · Journal of Ethnopharmacology (1984)
Santos, R. G., Landeira-Fernandez, J., Strassman, R. J. et al. · Journal of Ethnopharmacology (2007)
Winstock, A. R., Kaar, S., Borschmann, R. · Journal of Psychopharmacology (2013)
Strassman, R. J., Qualls, C .R. · JAMA Psychiatry (1994)
Timmermann, C., Roseman, L., Schartner, M. et al. · Scientific Reports (2019)
Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H. et al. · JAMA Psychiatry (1994)
Timmermann, C., Roseman, L., Williams, L. et al. · Frontiers in Psychology (2018)
Griffiths, R. R., Hurwitz, E. S., Davis, A. K. et al. · PLOS ONE (2019)
Cakic, V., Potkonyak, J., Marshall, A. · Drug and Alcohol Dependence (2010)
Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A. et al. · Pharmacopsychiatry (2005)
Show all 27 referencesShow fewer
Davis, A. K., Clifton, J. M., Weaver, E. G. et al. · Journal of Psychopharmacology (2020)
Valle, M., Maqueda, A. E., Rabella, M. et al. · European Neuropsychopharmacology (2016)
Barker, S. · Frontiers in Neuroscience (2018)
Nichols, D. E. · Journal of Psychopharmacology (2017)
Nayak, S., Gukasyan, N., Barrett, F. S. et al. · Pharmacopsychiatry (2021)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)
Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)
Frecska, E., Móré, C. E., Vargha, A. et al. · Journal of Psychoactive Drugs (2012)
Alamia, A., Timmermann, C., Carhart-Harris, R. L. · eLife (2020)
Riba, J., Anderer, P., Morte, A. et al. · British Journal of Clinical Pharmacology (2002)
Schenberg, E. E., Alexandre, J. F. M., Filev, R. et al. · PLOS ONE (2015)
Alonso, J. N., Romero, S., Mañanas, M. A. et al. · International Journal of Neuropsychopharmacology (2015)
Kaelen, M., Roseman, L., Kahan, J. et al. · European Neuropsychopharmacology (2016)
Timmermann, C., Spriggs, M. J., Kaelen, M. et al. · Neuropharmacology (2018)
Winkelman, M. J. · Frontiers in Neuroscience (2017)
Trichter, S., Klimo, J., Krippner, S. · Journal of Psychoactive Drugs (2009)
Cited By (17)
Papers in Blossom that reference this study
Goldy, S. P., Sepeda, N. D., Hilbert, S. N. et al. · Psychiatry Research (2026)
Lewis-Healey, E., Pallavicini, C., Cavanna, F. et al. · Journal of Cognitive Neuroscience (2025)
Falchi-Carvalho, M., Palhano-Fontes, F., Wießner, I. et al. · Neuropsychopharmacology (2025)
Singleton, S. P., Timmermann, C., Luppi, A. I. et al. · Communications Biology (2025)
Sanders, J. W., Milliere, R., Daily, Z. G. et al. · Preprints (2024)
Jiwani, Z., Goldberg, S. B., Stroud, J. et al. · MedRvix (2024)
Pais, M., Teixeira, M., Soares, C. et al. · NeuroImage (2024)
Pasquini, L., Simon, A. J., Gallen, C. L. et al. · Biorxiv (2024)
Timmermann, C., Zeifman, R. J., Erritzoe, D. et al. · Scientific Reports (2024)
Aicher, H. D., Mueller, M. J., Dornbierer, D. A. et al. · Frontiers in Psychiatry (2024)
Show all 17 papersShow fewer
David, J., Bouso, J. C., Kohek, M. et al. · Frontiers in Psychiatry (2023)
Dourron, H. M., Nichols, C. D., Simonsson, O. et al. · Psychopharmacology (2023)
Luan, L. X., Eckernäs, E., Ashton, M. et al. · Journal of Psychopharmacology (2023)
Lawrence, D. W., Timmermann, C. · Journal of Psychoactive Drugs (2023)
Timmermann, C., Roseman, L., Haridas, S. et al. · PNAS (2023)
Luppi, A. I., Hansen, J. Y., Adapa, R. et al. · Biorxiv (2022)
Friedman, S. F., Ballentine, G. · Biorxiv (2022)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.